Issue 3, 22 November 2006 Dear Shareholders Welcome to the third edition of Apollo Life, our regular newsletter to keep shareholders informed about our latest developments. If you would like any further information, please contact us. Regards John Priest - CEO

HOT TOPIC:

Stem cell hope for chemotherapy patients In a world first, Apollo Life Sciences has revealed that two of its human proteins are up to 53% faster in generating vital white blood cells used in the treatment of chemotherapy patients. This means cancer patients who normally have to wait for up to three weeks for white blood cell levels to regenerate before embarking on subsequent courses of chemotherapy can access potentially life saving treatments earlier.

ALSO IN THIS ISSUE:

Apollo begins tests of arthritis drugs in tablet form Apollo’s world-first technique for delivering arthritis drugs in tablet form is beginning animal trials. Apollo big in Japan Apollo has appointed a Japanese distributor to promote and distribute products from its portfolio of innovative human proteins and detection kits. Diabetes care for everyone World Diabetes Day on November 14 saw people around the globe unite to raise awareness of the condition.

Click here to subscribe

www.apollolifescience.com

 
Apollo Life Sciences Limited  ASX: AOP
Level 1, 147 Queen Street Beaconsfield NSW 2015 Australia
 
If you would prefer not to receive future email communications from Apollo Life Sciences, please
click here or reply to this message with the word REMOVE in the subject field.
You will receive one additional email confirming your removal.